课题基金 / 基金详情

Assessment of development of resistance to neuraminidase inhibitors in A (H5N1) influenza viruses using a ferret model

Assessment of development of resistance to neuraminidase inhibitors in A (H5N1) influenza viruses using a ferret model
使用雪貂模型评估甲型 (H5N1) 流感病毒对神经氨酸酶抑制剂的耐药性发展
批准号:
nhmrc : 400595
负责人:
A/Pr Aeron Hurt
金额:
$11.04万
依托单位:
依托单位国家:
澳大利亚
项目类别:
NHMRC Strategic Awards
财政年份:
2006
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2006-01-01 至 2007-12-31

项目摘要

项目成果

A/Pr Aeron Hurt的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The neuraminidase (NA) inhibitors are considered the most effective anti-influenza drugs available for both prevention and treatment of influenza virus infection including A(H5N1) viruses. The drugs are effective against all subtypes of influenza A, making them ideal for use in the early months of a pandemic prior to an appropriate vaccine being produced. As a result many countries around the world, including Australia, have stockpiled these drugs (mainly Tamiflu) as part of their pandemic preparedness plans. However, of concern is the increasing number of recent reports of a higher than expected level of resistance in epidemic influenza being generated against these drugs. A recent isolation of an H5N1 virus from a Vietnamese girl highlights that these viruses can also be resistant to Tamiflu. Within Australia, Tamiflu will be a critical weapon against the initial wave of an influenza pandemic, therefore it is vital that more is known about the propensity of the H5N1 virus to generate resistance, and possibly make these drugs clinically less effective. The aim of the project is to determine the levels, mode and type of resistance that may occur when ferrets are experimentally infected with HP A(H5N1) virus and then treated with NA inhibitors drugs such as Tamiflu. In the event of resistant viruses being isolated following drug pressure from Tamiflu, the strains will then be tested for their sensitivity to the other NA inhibitor drugs Relenza (zanamivir) or the peramivir (a third currently unlicensed NA inhibitor). The results from this cross resistance work will allow strategies to be put into place regarding the administration of an alternative NA inhibitor in the event of a pandemic virus acquiring particular NA mutations which may for example result in Tamiflu resistance. To determine the relative human risk of a NA inhibitor resistant A(H5N1) virus, studies to determine how infectious or transmissible the viruses are would be performed on all resistant strains isolated. NA inhibitor resistant strains demonstrate varying degrees of transmissibility and fitness, therefore it would be beneficial to classify this for any strains generated from this study so as to be in a better position to understand the public health implications if a particular resistant strain was to arise.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining the roles and targeting interferon-epsilon as a new therapy for influenza in asthma and COPD
  • 批准号:
    nhmrc : 1138004
  • 项目类别:
    Project Grants
  • 资助金额:
    $61.25万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Aeron Hurt
  • 依托单位:
Defining the roles and targeting interferon-epsilon as a new therapy for influenza in asthma and COPD
  • 批准号:
    nhmrc : GNT1138004
  • 项目类别:
    Project Grants
  • 资助金额:
    $90.59万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Aeron Hurt
  • 依托单位:
Low-Cost Portable Inhalation Therapy Platform for Needle-Free DNA-Based Influenza Vaccination
  • 批准号:
    nhmrc : GNT1112870
  • 项目类别:
    Development Grants
  • 资助金额:
    $52.46万
  • 财政年份:
    2016
  • 负责人:
    A/Pr Aeron Hurt
  • 依托单位:
Low-Cost Portable Inhalation Therapy Platform for Needle-Free DNA-Based Influenza Vaccination
  • 批准号:
    nhmrc : 1112870
  • 项目类别:
    Development Grants
  • 资助金额:
    $36.0万
  • 财政年份:
    2016
  • 负责人:
    A/Pr Aeron Hurt
  • 依托单位:
国内基金
海外基金
损伤线粒体传递机制介导成纤维细胞/II型肺泡上皮细胞对话在支气管肺发育不良肺泡发育阻滞中的作用
  • 批准号:
    82371721
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    王星云
  • 依托单位:
增强子在小鼠早期胚胎细胞命运决定中的功能和调控机制研究
  • 批准号:
    82371668
  • 项目类别:
    面上项目
  • 资助金额:
    52.00万元
  • 批准年份:
    2023
  • 负责人:
    乔云波
  • 依托单位:
MAP2的m6A甲基化在七氟烷引起SST神经元树突发育异常及精细运动损伤中的作用机制研究
  • 批准号:
    82371276
  • 项目类别:
    面上项目
  • 资助金额:
    47.00万元
  • 批准年份:
    2023
  • 负责人:
    严佳
  • 依托单位:
"胚胎/生殖细胞发育特性激活”促进“神经胶质瘤恶变”的机制及其临床价值研究
  • 批准号:
    82372327
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    马展
  • 依托单位: